CORT stock surge on Lyforli cancer treatment

What happened: On March 25, the FDA approved Corcept Therapeutics' (CORT) cancer drug, Lifyorli (relacorilant). Following this approval, Wolfe Research upgraded CORT to 'Peerperform' from 'Underperform' on March 26. On April 10, Corcept presented conclusive total survival results from its Phase 3 ROSELLA trial at the Society of Gynecologic Oncology Annual Meeting. These developments drove CORT stock up nearly 9% on March 25 and 19.7% on April 10, reaching $40.47.

Market impact: The biotechnology sector, particularly cancer treatment-focused companies, experienced a boost due to Corcept's success. Investors snapped up CORT shares, with the stock becoming one of the top-performing healthcare stocks mid-week. The FDA approval of Lifyorli and positive trial results reaffirmed Corcept's position as a profitable biotech stock to buy, driving up its valuation.

What to watch next: Investors should monitor the FDA's decision on Lifyorli's supplemental New Drug Application (sNDA) for the treatment of patients with metastatic endometrial carcinoma, expected in Q4 2023. Additionally, Corcept's upcoming earnings reports (Q2 2023 on August 1 and Q3 2023 on November 1) will provide insights into the company's financial health and potential further growth. Technical traders may also watch CORT's stock price action around the $40 level for potential breakouts or reversals.